INDV vs. BHC, RYTM, DCPH, ARVN, AMPH, GERN, MRUS, MLTX, RCKT, and VERA
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Bausch Health Companies (BHC), Rhythm Pharmaceuticals (RYTM), Deciphera Pharmaceuticals (DCPH), Arvinas (ARVN), Amphastar Pharmaceuticals (AMPH), Geron (GERN), Merus (MRUS), MoonLake Immunotherapeutics (MLTX), Rocket Pharmaceuticals (RCKT), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical preparations" industry.
Bausch Health Companies (NYSE:BHC) and Indivior (NASDAQ:INDV) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
Bausch Health Companies has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Bausch Health Companies presently has a consensus price target of $11.33, indicating a potential upside of 82.80%. Indivior has a consensus price target of $36.00, indicating a potential upside of 94.81%. Given Bausch Health Companies' stronger consensus rating and higher possible upside, analysts plainly believe Indivior is more favorable than Bausch Health Companies.
Indivior has a net margin of 0.44% compared to Indivior's net margin of -5.07%. Bausch Health Companies' return on equity of 842.72% beat Indivior's return on equity.
78.7% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 8.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Indivior has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bausch Health Companies had 4 more articles in the media than Indivior. MarketBeat recorded 12 mentions for Bausch Health Companies and 8 mentions for Indivior. Bausch Health Companies' average media sentiment score of 1.28 beat Indivior's score of 0.04 indicating that Indivior is being referred to more favorably in the news media.
Bausch Health Companies received 349 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 61.90% of users gave Bausch Health Companies an outperform vote.
Summary
Indivior beats Bausch Health Companies on 12 of the 18 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
